LASIK Alternatives: New Laser-Free Eye Treatment Shows Promise
- On February 29, 2024, Orasis Vision announced positive preliminary results from its first-in-human clinical trial of its non-ablative laser treatment for myopia (nearsightedness).
- Unlike LASIK, which removes corneal tissue using an excimer laser, Orasis's technology uses a femtosecond laser to create microscopic bubbles within the cornea.
- The initial trial demonstrated that the treatment was well-tolerated, with no serious adverse events reported. Preliminary results indicated a statistically critically important reduction in myopia in treated patients.
“`html
orasis Vision’s Non-Ablative laser Treatment Shows Promise in Early Clinical Trials
On February 29, 2024, Orasis Vision announced positive preliminary results from its first-in-human clinical trial of its non-ablative laser treatment for myopia (nearsightedness). This technology aims to reshape the cornea without removing tissue, possibly offering a safer and more reversible alternative to traditional LASIK surgery.The trial, conducted in Israel, involved 30 patients and focused on evaluating the safety and efficacy of the procedure.
How the Orasis Treatment Works
Unlike LASIK, which removes corneal tissue using an excimer laser, Orasis’s technology uses a femtosecond laser to create microscopic bubbles within the cornea. These bubbles induce a localized change in corneal curvature, effectively correcting refractive error. According to a company press release, the treatment is designed to be minimally invasive and preserve the corneal biomechanical integrity.
Key Findings from the Initial Trial
The initial trial demonstrated that the treatment was well-tolerated, with no serious adverse events reported. Preliminary results indicated a statistically critically important reduction in myopia in treated patients. Specifically, the average reduction in spherical equivalent was -0.50 diopters (D) at six months post-treatment, as reported in the February 29th press release. This suggests the treatment can effectively reduce nearsightedness.
While -0.50D may seem modest, it’s important to note this was a first-in-human trial focused on safety and proof-of-concept. Further optimization of treatment parameters is expected to yield greater refractive corrections in subsequent trials. The company also reported that the effect appeared stable over the six-month follow-up period.
| Metric | Value |
|---|---|
| Average Myopia Reduction | -0.50 Diopters |
| Trial Participants | 30 |
| Follow-up Period | 6 Months |
| Serious Adverse Events | 0 |
LASIK vs. Orasis: A Comparison
LASIK has been a widely adopted vision correction procedure for decades, but it’s not without risks. These include dry eye, glare, halos, and, in rare cases, corneal ectasia (weakening of the cornea). The U.S. Food and Drug Management (FDA) provides detailed information on LASIK risks and patient considerations.
Orasis’s non-ablative approach aims to mitigate some of these risks. By avoiding tissue removal, the treatment theoretically preserves corneal strength and reduces the likelihood of long-term complications.The reversibility of the corneal reshaping is another potential advantage, allowing for adjustments or further treatment if needed. However,it’s crucial to remember that this technology is still in early stages of advancement.